meta|Evidence - COVID-19
click on circles to display study description...
Early convalescent plasma. (n=28) vs. Deferred Convalescent plasma (n=30)
randomized controlled trial low risk of bias
Early plasma transfusion.
First plasma unit on the day of enrollment or 24h later.
Deferred plasma transfusion.
Only if a pre-specified worsening respiratory function criterion was met during hospitalization (Pa02/Fi02 <200) or if the patient still required hospitalization for symptomatic COVID-19 >7 days after enrollment.
Transfusions considered a total of 400 mL of ABO compatible convalescent plasma, infused as two 200 mL units, each separated by 24 hours. In both groups, cointerventions, including antibiotics, antivirals, heparin thromboprophylaxis, and immunomodulators, were allowed based on the hospital protocols. A total of 13 participants (43.3%) from the deferred plasma group received plasma
COVID 19 hospitalized
Patients over 18 years old, hospitalized, with COVID-19 symptoms present at enrollment and confirmed with a positive SARS-CoV-2 realtime PCR in nasopharyngeal swab, or pending PCR result and with imaging consistent with COVID-19 pneumonia and confirmed COVID-19 close contact, =< 7 days from COVID-19 symptom onset to enrollment, a CALL score >= 9 points at enrollment (predicts high risk of progression into respiratory failure, based on age, comorbidities, lactate dehydrogenase [LDH], and lymphocyte count); and Eastern Cooperative Oncology Group (ECOG) performance status before SARS-CoV-2 infection 0–2. Patients with PaO2/FiO2<200 or on mechanical ventilation at enrollment were excluded.
Open-label.
Single-center, Chilean medical center in Santiago, Chile.
Phase II.
Phase II.
powered by vis.js Network